1. Home
  2. CSAN vs TVTX Comparison

CSAN vs TVTX Comparison

Compare CSAN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cosan S.A. ADS

CSAN

Cosan S.A. ADS

HOLD

Current Price

$2.89

Market Cap

4.2B

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$58.35

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSAN
TVTX
Founded
1936
N/A
Country
Brazil
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.3B
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
CSAN
TVTX
Price
$2.89
$58.35
Analyst Decision
Hold
Strong Buy
Analyst Count
2
13
Target Price
$4.75
$40.62
AVG Volume (30 Days)
2.7M
2.2M
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.89
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$321.51
$44.76
Revenue Next Year
$3.57
$35.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.52
$14.36
52 Week High
$6.01
$57.85

Technical Indicators

Market Signals
Indicator
CSAN
TVTX
Relative Strength Index (RSI) 46.22 78.50
Support Level $2.52 $41.75
Resistance Level $4.37 N/A
Average True Range (ATR) 0.12 2.31
MACD 0.07 0.72
Stochastic Oscillator 98.81 99.86

Price Performance

Historical Comparison
CSAN
TVTX

About CSAN Cosan S.A. ADS

Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: